Non-Invasive Ocular Delivery Platform for Brain Therapeutics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering compounds to the brain and central nervous system are invasive, inefficient, and face challenges such as low drug penetration across the blood-brain barrier, invasiveness, and high clinical failure rates for neurodegenerative diseases like Alzheimer's and Parkinson's.
Innovation Solution
A non-invasive ocular delivery platform (NIODP) is used to administer compounds, including omega-3 fatty acids, through the periorbital or eyelid skin, leveraging the trans-ocular/retinal transport pathway to effectively deliver therapeutic agents to the brain and central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If invasive methods are used to deliver compounds to the brain, then delivery efficiency improves, but patient safety and comfort deteriorate
Solution Approach 1:
The invention uses the periorbital skin and ocular tissues as an intermediary pathway to deliver compounds to the brain. Instead of directly invasive methods, the composition is applied topically to the periorbital skin, which serves as a gateway for transdermal delivery through hair follicles and sebaceous glands, ultimately reaching the brain via the optic nerve pathway.
2Ease of operation
If topical administration is used, then patient comfort improves, but drug penetration across the blood-brain barrier deteriorates
Solution Approach 1:
The invention applies local quality by using penetration enhancers specifically in the periorbital skin formulation to improve local absorption. The composition includes compounds like DMSO, ethanol, or fatty acids that enhance percutaneous penetration at the application site, allowing sufficient drug concentration to reach the brain through the unique periorbital pathway without requiring systemic high doses.
Solution Approach 2:
The invention utilizes the periorbital skin and ocular tissues as an intermediary pathway that bypasses the typical blood-brain barrier limitations. The composition is designed to penetrate the periorbital skin, enter the ocular tissues, and reach the brain through the optic nerve, providing an alternative route that maintains patient comfort while achieving reliable brain penetration.
3Quantity of substance
If high doses are administered, then therapeutic effect improves, but safety profile deteriorates
Solution Approach 1:
The periorbital delivery system acts as a localized intermediary pathway that allows for targeted delivery of therapeutic doses directly to the brain without requiring high systemic doses. This localized route enables sufficient brain concentration achievement with lower overall drug quantities, thereby improving the safety profile by reducing systemic exposure and potential side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for efficient and non-invasive delivery of therapeutic compounds to the brain, reducing treatment burden and potentially treating a wide range of CNS diseases, including neurodegenerative disorders, with improved safety and efficacy profiles.
Implementation Method 1
administering a topical pharmaceutical composition comprising an omega-3 fatty acid to the periorbital skin or eyelid of an eye of the subject
Data Source
AI summary
Described herein are compositions and methods for the topical administration of various compounds to the periorbital and eyelid region of the eye. Such compositions and methods are useful for treating various brain and central nervous system diseases and disorders, as well as in promoting general brain and central nervous system health.